Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

Conditions:   HER2-positive Breast Cancer;   Stage I Breast Cancer Intervention:   Biological: Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination Sponsors:   Fundacio Clinic Barcelona;   SOLTI Breast Cancer Research Group;   Roche Pharma AG Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Condition:   Mammary Cancer Interventions:   Drug: Pertuzumab and trastuzumab FDC subcutaneous;   Drug: Paclitaxel;   Drug: TDM1;   Drug: Endocrine therapy;   Procedure: Omission surgery Sponsors:   David Garcia Cinca;   Fundacion Clinic per a la Recerca Biomédica Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
art M Abstract HER2+ early breast cancer is a heterogeneous disease, comprising all the intrinsic breast cancer subtypes. The only biomarker available nowadays for anti-HER2 treatment selection is HER2 status itself, but estrogen receptor (ER) status is emerging as a robust predictive marker within HER2+ disease. In this Perspective, we discuss the biological and clinical differences between patients with HER2+/ER positive (ER+) disease versus those with HER2+/ER negative (ER-neg) tumors, namely short- and long-term (>5 years after diagnosis) prognosis, response to neoadjuvant treatment and benefit from adjuvan...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Breast cancer is a highly heterogeneous disease with various molecular subtypes that differ in regard to treatment approach as well as unresolved treatment issues.In women with HER2-amplified breast tumors, standard neoadjuvant therapy consisting of dual HER2 blockade with trastuzumab/pertuzumab plus chemotherapy can induce a high pathologic complete response (pCR) rate (60%), which translates into better overall survival (>90% at 3 years). A critical unresolved issue in the neoadjuvant treatment of HER2-amplified tumors is minimizing toxicity in select patients. Selection of non-cardiogenic regimens and chemotherapy-fr...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Invited Speaker Abstracts Source Type: research
The epidermal growth factor receptor-2 (HER2) is a member of the HER family, a robust and complex signaling network with multiple redundant inputs (ligands and receptors), central signals, and ample feedback routes. HER2 amplification occurs in about 15% of breast cancers and is a major driver of cell proliferation and survival. Therapies targeting HER2, including the monoclonal antibodies trastuzumab and pertuzumab, the trastuzumab drug conjugate T-DM1, and the HER1/2 tyrosine kinase inhibitor lapatinib, have substantially improved outcome of patients with this subtype of disease. Stemming from preclinical evidence, in re...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Invited Speaker Abstracts Source Type: research
BACKGROUND: Many different scales have been developed in order to assess response to NAC. Apart from Miller and Payne and RCB systems, recently the addiction of post-NAC pathological Ki 67 (yp Ki67) to RCB, called RPCB system, has been considered as a more accurate prognostic tool. The aim of this study is to assess the prognosis value of RPCB in a routine practice cohort and to compare it to RCB index and ypKi67.METHODS: We performed a retrospective analysis of our database. Patients with stage I-III considered candidate for NAC from July 2008 and August 2011 were included. RPCB and RCB were calculated as previously publi...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Addiction | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Neoadjuvant Therapy | Research